These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. Fattorini L; Tan D; Iona E; Mattei M; Giannoni F; Brunori L; Recchia S; Orefici G Antimicrob Agents Chemother; 2003 Jan; 47(1):360-2. PubMed ID: 12499213 [TBL] [Abstract][Full Text] [Related]
23. Should moxifloxacin be substituted for isoniazid as a first-line antituberculosis drug? Mohapatra PR Am J Respir Crit Care Med; 2009 Oct; 180(7):686; author reply 686-7. PubMed ID: 19762595 [No Abstract] [Full Text] [Related]
24. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Ji B; Chauffour A; Robert J; Jarlier V Antimicrob Agents Chemother; 2008 Jun; 52(6):1912-6. PubMed ID: 18391038 [TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Zhang M; Sala C; Dhar N; Vocat A; Sambandamurthy VK; Sharma S; Marriner G; Balasubramanian V; Cole ST Antimicrob Agents Chemother; 2014 Jun; 58(6):3217-23. PubMed ID: 24663022 [TBL] [Abstract][Full Text] [Related]
31. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Rodríguez JC; Ruiz M; Climent A; Royo G Int J Antimicrob Agents; 2001 Mar; 17(3):229-31. PubMed ID: 11282270 [TBL] [Abstract][Full Text] [Related]
32. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. Gillespie SH; Gosling RD; Uiso L; Sam NE; Kanduma EG; McHugh TD J Antimicrob Chemother; 2005 Dec; 56(6):1169-71. PubMed ID: 16223939 [TBL] [Abstract][Full Text] [Related]
33. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. Cremades R; Rodríguez JC; García-Pachón E; Galiana A; Ruiz-García M; López P; Royo G J Antimicrob Chemother; 2011 Oct; 66(10):2281-3. PubMed ID: 21733966 [TBL] [Abstract][Full Text] [Related]
34. Trial tests new combination of drugs to treat tuberculosis. Roehr B BMJ; 2012 Mar; 344():e2216. PubMed ID: 22434129 [No Abstract] [Full Text] [Related]
35. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. Hillemann D; Rüsch-Gerdes S; Richter E J Clin Microbiol; 2009 Jun; 47(6):1767-72. PubMed ID: 19386845 [TBL] [Abstract][Full Text] [Related]
36. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol. Malik M; Drlica K Antimicrob Agents Chemother; 2006 Aug; 50(8):2842-4. PubMed ID: 16870782 [TBL] [Abstract][Full Text] [Related]
37. Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. Musuka S; Srivastava S; Siyambalapitiyage Dona CW; Meek C; Leff R; Pasipanodya J; Gumbo T Antimicrob Agents Chemother; 2013 Dec; 57(12):5870-7. PubMed ID: 24041886 [TBL] [Abstract][Full Text] [Related]
38. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Pletz MW; De Roux A; Roth A; Neumann KH; Mauch H; Lode H Antimicrob Agents Chemother; 2004 Mar; 48(3):780-2. PubMed ID: 14982764 [TBL] [Abstract][Full Text] [Related]